Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Infliximab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    417 result(s) found for: Infliximab. Displaying page 1 of 21.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-004969-14 Sponsor Protocol Number: 2111 Start Date*: 2014-01-28
    Sponsor Name:Heidi Mäkinen
    Full Title: Measurement of levels of infliximab and anti-infliximab antibodies in rheumatic patients
    Medical condition: rheumatic diseases
    Disease: Version SOC Term Classification Code Term Level
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10072736 Rheumatic disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004012-10 Sponsor Protocol Number: MODIFI Start Date*: 2021-06-17
    Sponsor Name:UZ Leuven
    Full Title: Model-informed infliximab dose de-escalation following earlier dose escalation in adult patients with inflammatory bowel diseases
    Medical condition: Inflammatory bowel diseases - Crohn's disease - ulcerative colitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004904-31 Sponsor Protocol Number: IFX4501 Start Date*: 2015-05-19
    Sponsor Name:Mundipharma Pharmaceuticals B.V.
    Full Title: An open-label, multicentre, phase IV study to investigate the infliximab serum concentration of Remsima™ (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn’s ...
    Medical condition: Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000570-28 Sponsor Protocol Number: IFX001PSHP Start Date*: 2021-11-09
    Sponsor Name:Tampere University Hospital
    Full Title: Accelerated infliximab infusions in inflammatory bowel disease, Phase IV trial
    Medical condition: Inflammatory bowel diseases
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-004463-25 Sponsor Protocol Number: RHMMED1716 Start Date*: 2020-12-15
    Sponsor Name:University Hospital Southampton NHS Trust
    Full Title: SWitching InflixiMab to SUbcut from Intravenous Therapy
    Medical condition: Crohn's Disease Ulcerative Colitis Rheumatoid Arthritis Psoriatic Arthritis Ankylosing Spondylitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-002027-16 Sponsor Protocol Number: RPCG06B2433 Start Date*: 2006-12-12
    Sponsor Name:UCB AE
    Full Title: Certolizumab pegol 400 mg monthly in the treatment of adult Greek patients with moderate to severe Crohn’s Disease, who have been previously treated successfully with infliximab but who have subseq...
    Medical condition: Certolizumab pegol in the treatment of adult Greek patients with moderate to severe Crohn’s Disease, who have been previously treated successfully with infliximab but who have subsequently lost the...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2008-007519-34 Sponsor Protocol Number: FAST VERSION Start Date*: 2009-04-17
    Sponsor Name:University of Leuven Hospitals, Division of Gastroenterology
    Full Title: Feasibility of Accelerated infliximab infusions - Safety and Tolerability in patients wit IBD. FAST
    Medical condition: This is a open label, prospective, multicenter trial in patients recieving one hour infusions of infliximab (i.e. Remicade)as part of their daily practice. Main objective: Is to assess the tolerab...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002460-29 Sponsor Protocol Number: EASIC30505 Start Date*: 2005-09-12
    Sponsor Name:Rheumazentrum Ruhrgebiet.
    Full Title: An Open Extension, Investigator Initiated Trial, to Examine Radiographic Progression, Efficacy and Safety, of Long-Term Treatment with Infliximab in Patients with Ankylosing Spondylitis EASIC...
    Medical condition: Ankylosing spondylitis (AS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FI (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004148-49 Sponsor Protocol Number: B5371002 Start Date*: 2014-07-14
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY ASSESSING THE EFFICACY AND SAFETY OF PF-06438179 AND INFLIXIMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID A...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) CZ (Completed) GB (Completed) HU (Completed) DE (Completed) PL (Completed) BG (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-005629-21 Sponsor Protocol Number: Tech-infliximab2014/1 Start Date*: 2014-08-14
    Sponsor Name:First Department of Medicine, University of Szeged
    Full Title: Diagnostic use of 99mTecnetium labeled infliximab in Crohn’s disease
    Medical condition: Crohn’s disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002098-25 Sponsor Protocol Number: ZKSJ0137_INFLIXCOVID Start Date*: 2021-05-27
    Sponsor Name:Friedrich-Schiller-Universität Jena
    Full Title: A randomized, controlled, multicenter, open label phase II clinical study to evaluate infliximab in the treatment of patients with severe COVID-19 disease (INFLIXCOVID)
    Medical condition: severe COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001131-35 Sponsor Protocol Number: 08-0106-stop Start Date*: 2008-05-14
    Sponsor Name:Academic Medical Center, department of Gastroenterology and hepatology
    Full Title: Azathioprine maintenance treatment versus Infliximab maintenance treatment in Crohn's disease patients in remission: a randomized multicenter trial
    Medical condition: this study is designed as a multicenter radomized trial comparing azathioprine maintenance treatment to infliximab maintenance treatment in Crohn's disease patients that are in remission for at lea...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-006022-32 Sponsor Protocol Number: P160922 Start Date*: 2021-04-07
    Sponsor Name:Assistance Publique Hôpitaux de Paris (APHP)
    Full Title: TNF-alpha antagonists (Infliximab) withdrawal in sarcoidosis : a prospective, randomized, controlled trial
    Medical condition: sarcoidosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-002311-41 Sponsor Protocol Number: 2014-3 Start Date*: 2014-08-12
    Sponsor Name:GETAID
    Full Title: A proSpective randomized controlled trial comParing infliximAb-antimetabolites combination therapy to anti-metabolites monotheRapy and infliximab monothErapy in Crohn’s disease patients in sustaine...
    Medical condition: Luminal Crohn’s disease patients with steroid free remission for at least 6 months and a combination therapy with infliximab and anti-metabolites for at least 1 year
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) GB (GB - no longer in EU/EEA) SE (Ongoing) DE (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-013869-26 Sponsor Protocol Number: P06119 Start Date*: 2009-10-02
    Sponsor Name:Associação para Desenvolvimento da Dermatologia do Hospital de Santa Maria
    Full Title: "Influence of Remicade (infliximab) in the skin proteome of psoriatic patients"
    Medical condition: This pilot lab-based study will assess skin biopsies from psoriatic patients treated with infliximab and aim to compare the proteomic profiles of samples obtained under the following conditions: 1-...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10037153 Psoriasis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-002224-26 Sponsor Protocol Number: INFLIXIMABDOSE01 Start Date*: 2015-05-07
    Sponsor Name:St. Antonius Hospital
    Full Title: A new dosing strategy of infliximab versus standard dosing in patients with severe sarcoidosis: optimization of treatment
    Medical condition: Sarcoidosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001853-17 Sponsor Protocol Number: AGO/2008/003 Start Date*: 2008-06-26
    Sponsor Name:University Hospital Ghent
    Full Title: Invloed van behandeling met infliximab op immuuncellen in het bloed van patiënten met spondyloartritis
    Medical condition: spondyloartritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058338 Spondylarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002651-15 Sponsor Protocol Number: 000001 Start Date*: 2014-03-03
    Sponsor Name:Zon MW
    Full Title: Adjusting infliximab dose in IBD patients in remission, based on infliximab trough levels: the study on Infliximab Levels in IBD patients Steering Treatment, the ILIST pilot
    Medical condition: Crohns disease Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    19.0 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004618-10 Sponsor Protocol Number: PACIFIC Start Date*: 2016-04-19
    Sponsor Name:CUB- Hopital Erasme
    Full Title: Study of the inter-individual variation of PhArmaCo-kinetics of InFliximab during treatment Induction in patients with Crohn’s disease and Ulcerative Colitis
    Medical condition: Patients with Crohn disease or Ulcerative Colitis which need biotherapy (antibody against TNF-a)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002673-21 Sponsor Protocol Number: 35RC17_8841_EFFICACI Start Date*: 2018-09-04
    Sponsor Name:Centre Hospitalier Universitaire de Rennes
    Full Title: EFFICACI : EFFicacy of intravenous Infliximab versus vedolizumab after failure of subCutaneous Anti-TNF in patients with UlCerative colitis : A double blinded Randomized Clinical Trial.
    Medical condition: Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 23:31:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA